SGX queries Biolidics on A*Star licence deal

Singapore

THE Singapore Exchange (SGX) on Wednesday posed a series of queries to Biolidics about the details of a licence agreement the Catalist-listed firm had inked as well as the timing of its trading halt and announcement.

In a filing late Tuesday night, Biolidics said it had on July 9 entered into a five-year licence agreement with Accelerate Technologies, the commercialisation arm of the Agency for Science, Technology and Research (A*Star), to use the agency's technology for the detection of Covid-19 viral spike/Angiotensin-Converting Enzyme 2 (ACE2) blocking antibodies.